Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

994 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Wolchok JD, et al. Among authors: dummer r. N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11. N Engl J Med. 2017. PMID: 28889792 Free PMC article. Clinical Trial.
Serological detection of cutaneous T-cell lymphoma-associated antigens.
Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Eichmuller S, et al. Among authors: dummer r. Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):629-34. doi: 10.1073/pnas.98.2.629. Epub 2001 Jan 9. Proc Natl Acad Sci U S A. 2001. PMID: 11149944 Free PMC article.
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
Keilholz U, Martus P, Punt CJ, Kruit W, Mooser G, Schadendorf D, Liénard D, Dummer R, Koller J, Voit C, Eggermont AM. Keilholz U, et al. Among authors: dummer r. Eur J Cancer. 2002 Jul;38(11):1501-11. doi: 10.1016/s0959-8049(02)00123-5. Eur J Cancer. 2002. PMID: 12110497 Clinical Trial.
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R. Hauschild A, et al. Among authors: dummer r. J Clin Oncol. 2003 Aug 1;21(15):2883-8. doi: 10.1200/JCO.2003.07.116. J Clin Oncol. 2003. PMID: 12885805 Clinical Trial.
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krengel S, Kretschmer L, Garbe C, Dummer R; Dermatologic Cooperative Oncology Group. Kaufmann R, et al. Among authors: dummer r. J Clin Oncol. 2005 Dec 10;23(35):9001-7. doi: 10.1200/JCO.2005.01.1551. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260697 Clinical Trial.
994 results